Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Director/PDMR Shareholding

3 Jun 2013 13:48

Tate & Lyle PLC

Director/PDMR Shareholding

Tate & Lyle PLC (the “Company”) was informed on 31 May 2013 of the following transactions under the Company’s Group Bonus Plan (‘GBP’) by PDMRs on that day:

Name

No of sharesreleased

No. of shares disposedof at 827.92 pence pershare to pay for taxand sale costs

No. of sharesretained

Karl Kramer 35,959 16,943 19,016
Olivier Rigaud 14,941 7,047 7,894
Matt Wineinger 45,156 14,660 30,496

No consideration was paid for the acquisition of these shares and all transactions occurred on the London Stock Exchange.

The above awards were made under the GBP in 2011 and were subject to the satisfaction of employment conditions. Details of the operation of the GBP are contained within the Annual Report 2011.

This notification is made in accordance with DTR 3.1.4R(1)(a) of the Disclosure and Transparency Rules.

Lucie GilbertCompany Secretary

3 June 2013

Copyright Business Wire 2013

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.